Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms

Tristan M. Sissung, Cody J. Peer, Neha Korde, Sham Mailankody, Dickran Kazandjian, David J. Venzon, Ola Landgren, William D. Figg

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The combination of carfilzomib, lenalidomide, and dexamethasone (CRd) has induced deep responses in patients with newly diagnosed multiple myeloma. While vascular endothelial growth factor (VEGF) pathway polymorphisms have been associated with clinical outcomes for antiangiogenesis agents, we explored associations between such polymorphisms and CRd clinical response. The VEGF-1498C>T (rs833061) and VEGFR2 V297I (rs2305948) were associated with CRd response (OR ≤ 0.10, P ≤ 0.009), whereas VEGF-1498C>T and VEGFR2 Q472H (rs1870377) were associated with minimum residual disease negativity (P ≤ 0.023). As these SNPs were not associated with disease parameters (e.g., plasma VEGF, albumin, or beta-2-microglobin concentration), data suggest these SNPs may be markers of CRd response.

Original languageEnglish (US)
Pages (from-to)217-221
Number of pages5
JournalCancer Chemotherapy And Pharmacology
Volume80
Issue number1
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Keywords

  • Carfilzomib
  • KDR
  • Lenalidomide
  • Multiple myeloma
  • Polymorphism
  • Vascular endothelial growth factor
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms'. Together they form a unique fingerprint.

Cite this